Cargando…

CXCR3 blockade: a novel anti-sepsis approach?

Blockade of the CXC chemokine receptor 3 (CXCR3) attenuates inflammation and improves survival in a murine model of near lethal polymicrobial sepsis. However, given the multitude of cellular responses and inflammatory mediators that orchestrate sepsis syndrome, more detailed investigations will be r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delano, Matthew J, Moldawer, Lyle L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672571/ https://www.ncbi.nlm.nih.gov/pubmed/23171733 http://dx.doi.org/10.1186/cc11818

Ejemplares similares

Therapeutic efficacy of CXCR3 blockade in an experimental model of severe sepsis
por: Herzig, Daniela S, et al.
Publicado: (2012)

Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10
por: Kelly-Scumpia, Kindra M., et al.
Publicado: (2010)

Sepsis-associated delirium: the pro and con of C5a blockade
por: Annane, Djillali
Publicado: (2009)

Immunological Defects in Neonatal Sepsis and Potential Therapeutic Approaches
por: Raymond, Steven L., et al.
Publicado: (2017)

CXCR3: Here to stay to enhance cancer immunotherapy?
por: Rogava, Meri, et al.
Publicado: (2019)

Recently published papers: Sepsis – guidelines, treatment and novel approaches
por: Kalsi, Navneet, et al.
Publicado: (2008)

IL-6 Blockade as a Therapeutic Approach for Duchenne Muscular Dystrophy
por: Mammen, Andrew L., et al.
Publicado: (2015)

A Review of GM-CSF Therapy in Sepsis
por: Mathias, Brittany, et al.
Publicado: (2015)

CXCR4 blockade decreases CD4(+) T cell exhaustion and improves survival in a murine model of polymicrobial sepsis
por: Ramonell, Kimberly M., et al.
Publicado: (2017)

How to approach genome wars in sepsis?
por: Hawiger, Jack, et al.
Publicado: (2011)

Dysregulated Immunity and Immunotherapy after Sepsis
por: Darden, Dijoia B., et al.
Publicado: (2021)

B cells enhance early innate immune responses during bacterial sepsis
por: Kelly-Scumpia, Kindra M., et al.
Publicado: (2011)

From the International Pediatric Sepsis Conference 2005 to the Sepsis-3 Consensus
por: de Souza, Daniela Carla, et al.
Publicado: (2018)

Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness
por: Barker, Grant, et al.
Publicado: (2021)

Penkid: A Novel Biomarker of Reduced GFR in Sepsis
por: Moledina, Dennis G.
Publicado: (2018)

Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration
por: Bazan, Nicolas G., et al.
Publicado: (2021)

Back From the Brink: The Uses of Targeting the CXCL10:CXCR3 Axis in Type 1 Diabetes
por: Homann, Dirk
Publicado: (2015)

Older adults show biomarker evidence of PICS after sepsis
por: Mankowski, Robert, et al.
Publicado: (2021)

Update on checkpoint blockade therapy for lymphoma
por: Kline, Justin, et al.
Publicado: (2015)

Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?
por: Van den Bosch, Filip, et al.
Publicado: (2005)

195 Older adults show biomarker evidence of PICS after sepsis
por: Mankowski, Robert, et al.
Publicado: (2022)

Brief comments on three existing approaches for managing neonates at risk of early-onset sepsis
por: Vaccina, E., et al.
Publicado: (2021)

Sepsis-3: How useful is the new definition?
por: Sinha, Sharmili, et al.
Publicado: (2018)

Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?
por: Hoffmann, Ursula, et al.
Publicado: (2009)

Blockade of the CXCR3/CXCL10 axis ameliorates inflammation caused by immunoproteasome dysfunction
por: Sasaki, Yuki, et al.
Publicado: (2022)

The International Sepsis Forum's controversies in sepsis: how will sepsis be treated in 2051?
por: Marshall, John C
Publicado: (2002)

The International Sepsis Forum's controversies in sepsis: how will sepsis be treated in 2051?
por: Abraham, Edward
Publicado: (2002)

Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little?
por: Golan, Yoav
Publicado: (2009)

Efficacy and safety of immune checkpoint blockade for brain metastases
por: Harary, Maya, et al.
Publicado: (2019)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
por: Ostriker, Allison C., et al.
Publicado: (2015)

The Puzzle of Predicting Response to Immune Checkpoint Blockade
por: Onyshchenko, Mykola
Publicado: (2018)

Predicting clinical response to costimulation blockade in autoimmunity
por: Edner, Natalie M, et al.
Publicado: (2020)

Older Sepsis Survivors Suffer Persistent Disability Burden and Poor Long-Term Survival
por: Mankowski, Robert, et al.
Publicado: (2020)

Death to sepsis: targeting apoptosis pathways in sepsis
por: Wheeler, Derek S
Publicado: (2009)

Age and Sex Influence the Hippocampal Response and Recovery Following Sepsis
por: Barter, Jolie, et al.
Publicado: (2019)

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
por: Naidoo, Jarushka, et al.
Publicado: (2017)

The International Sepsis Forum's frontiers in sepsis: high cardiac output should be maintained in severe sepsis
por: Vincent, Jean-Louis
Publicado: (2003)

The International Sepsis Forum's frontiers in sepsis: high cardiac output should not be maintained in severe sepsis
por: Sharma, Vinay K, et al.
Publicado: (2003)

Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury
por: Piotrowska, Anna, et al.
Publicado: (2019)

Extracellular Blockade of Potassium Channels by TEA(+): The Tip of the Iceberg?
por: Roux, Benoît
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_quggu1gg5shu5mkbigjpq9bo1c